Elsevier

Metabolism

Volume 45, Supplement 1, August 1996, Pages 17-20
Metabolism

Binding properties of somatostatin receptor subtypes

https://doi.org/10.1016/S0026-0495(96)90072-4Get rights and content

Abstract

In the past few years, five different somatostatin (SRIF) receptor subtypes (sst1–5) have been identified, which form a distinct group in the superfamily of G-protein—coupled receptors. The naturally occurring somatostatins SRIF-28, SRIF-25, and SRIF-14 all reveal high-affinity binding for sst1–5. In contrast, short synthetic analogs that are in clinical use, such as SMS 201–995, RC 160, or BIM 23014, primarily interact with the sst2 subtype. Some SRIF analogs were previously reported to be selective for one SRIF receptor subtype, eg, the sst2 (MK 678), the sst3 (BIM 23056), or the sst5 (BIM 23052, L362–L855) subtype. However, when we studied the binding affinities of these SRIF analogs for human (h) sst1–5 expressed in either CHO or COS-1 cells, we were unable to confirm these previously reported selectivities. The absence of sst antagonists is a major drawback for investigating the functional role of each sst subtype. We used site-directed mutagenesis to identify amino acids that determine ligand specificity for sst2. A single Ser305 to Phe mutation in TM VII increased the affinity of hsst1 for SMS 201–995 nearly 100-fold, and when Gln291 was also exchanged to Asn in TM VII of hsst1, almost full sst2-like binding of SMS 201–995 was obtained. These data may aid in the design and synthesis of new selective type sst ligands. We have identified the expression of sst subtypes in nonclassical SRIF target tissue such as the lung. The pKi values for SRIF and various SRIF analogs in rat lung tissue preparations were in close correlation with those obtained for CHO cells expressing the sst4 subtype. Furthermore, reverse transcriptase polymerase chain reaction (RT-PCR) experiments revealed the predominant expression of mRNA specific for sst4 in mouse, rat, and human lung tissue, confirmed by autoradiographies of rat lung. No specific binding for [125I]Tyr3-SMS 201–995 was detected, since SMS 201–995 has low affinity for sst4. In contrast, specific binding of [125I]SRIF-28 to rat lung sections was demonstrated, which could be displaced by unlabelled SRIF-14 and SRIF-28, indicating specific, high affinity binding of this radioligand to sst4 receptors.

References (15)

There are more references available in the full text version of this article.

Cited by (115)

  • Morpho-functional analysis of the early changes induced in retinal ganglion cells by the onset of diabetic retinopathy: The effects of a neuroprotective strategy

    2022, Pharmacological Research
    Citation Excerpt :

    Three days after STZ injection, 9 mice from the STZ-treated group were randomly assigned to the OCT treatment group and intravitreally injected with 1 µl of an OCT (Sigma-Aldrich) solution containing an amount of OCT to reach a final intravitreal OCT concentration of about 1 mM (considering a vitreous volume of 5 µl). According to previous studies, 1 mM OCT is a concentration giving maximal receptor occupancy in different systems [27–30], including the mouse retina [20,31,32]. Nine mice from the control group were also intravitreally injected with OCT.

  • Microscale radiosynthesis, preclinical imaging and dosimetry study of [<sup>18</sup>F]AMBF<inf>3</inf>-TATE: A potential PET tracer for clinical imaging of somatostatin receptors

    2018, Nuclear Medicine and Biology
    Citation Excerpt :

    In contrast, [18F]FDG imaging, a measure of tissue glucose metabolic activity, showed a reverse pattern with lower [18F]FDG metabolism in AR42J tumors than RM1 tumors (2.44 ± 0.57%ID/g and 5.25 ± 2.14%ID/g, respectively; p < 4.4e-2). Similarities in somatostatin peptide binding affinity between mouse and human SSTR2 suggest that mouse dosimetry provides a good estimation for human dosimetry [65,66]. Absorbed doses for [18F]AMBF3-TATE in humans were extrapolated from mouse PET biodistribution data using two extrapolation methods, Method 1 and Method 2 (see Supplementary Information, Section 4).

View all citing articles on Scopus
View full text